Clinical Trials
2 trialsNCT05073250 2023-05-12
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Chinese PLA General Hospital
Phase 2 Unknown
NCT00989586 2017-02-06
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed